With 2025's pharma M&A spend exceeding $150 billion—going by deals reported on by The Pharma Letter—the total was higher than ...

Charlie Gayer will become BioCryst's (Nasdaq: BCRX) new chief executive effective January 1. Currently the company’s chief ...

German drug developer InflaRx, which is developing anti-inflammatory therapeutics by targeting the complement system, has ...

Chinese biopharma Hutchmed today announces that the New Drug Application (NDA) for savolitinib for the treatment of locally ...

US clinical-stage biopharma Biohaven has reported disappointing results from a Phase II proof-of-concept study evaluating BHV ...

Privately-held Italian drugmaker Italfarmaco and Japanese drugmaker JCR Pharmaceuticals have announced an exclusive licensing ...

US biotech Ultragenyx Pharmaceutical saw its shares tumble over 43% to $19.41 yesterday, after it announced results from the ...

Privately-held US biotech QurAlis Corporation has announced topline data from its Phase I proof-of-mechanism (PoM) trial of ...

The US Food and Drug Administration (FDA) spent much of 2025 in the spotlight. Through steady drug approvals, renewed ...

Indian pharma. Exports and policy support remained important, but the more meaningful shift was in what people focused on ...

The Russian antitrust regulator – the Federal Antimonopoly Service (FAS) seems to be losing its legal battles with domestic ...

A conference and expo focused on how digital innovation is reshaping the pharmaceutical industry. The programme brings ...